rAAV‑mediated Hsp70 gene delivery alleviates FUS‑associated ALS‑like pathology
This study demonstrates that AAV-mediated delivery of the Hsp70 gene significantly extends survival and delays symptomatic progression in a transgenic mouse model of FUS-associated ALS, highlighting its potential as a disease-modifying therapeutic strategy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human brain relies on a delicate internal balance to keep its cells healthy. Proteins, the tiny machines that build and run every cell, must fold into precise shapes to work correctly. When these proteins misfold or clump together into sticky masses, they can poison the cell, leading to a slow breakdown of the nervous system. This process of protein clumping is a hallmark of several devastating diseases, including amyotrophic lateral sclerosis, or ALS. In some forms of ALS, a specific protein called FUS becomes toxic, forming aggregates that disrupt the life of motor neurons, the nerve cells responsible for telling muscles to move. Currently, treatments for these conditions mostly manage symptoms rather than stopping the underlying cause. Scientists have long suspected that boosting the body's natural cleanup crew—molecules known as heat shock proteins, which help refold damaged proteins—could offer a way to clear these toxic clumps and protect the brain.
A team of researchers recently tested this idea in a living model of the disease. They focused on a specific type of heat shock protein called Hsp70, which acts like a cellular repairman, helping to untangle misfolded proteins and prevent them from forming deadly aggregates. To deliver this repair protein directly into the brain and spinal cord, the scientists used a modified virus, known as an adeno-associated virus, which is harmless to humans but excellent at carrying genetic instructions into cells. They engineered this virus to carry the gene for Hsp70 and injected it into the bloodstream of mice genetically programmed to develop an ALS-like condition caused by the toxic FUS protein. The goal was to see if flooding the nervous system with this repair protein could slow the disease's progression and extend the animals' lives.
The results showed that the treatment worked, but only when delivered in a sufficiently large amount. The researchers divided the sick mice into three groups: one received no treatment, one received a low dose of the virus, and one received a high dose. The mice that received the high dose lived significantly longer than the untreated ones. On average, the treated mice survived for about 172 days, whereas the untreated mice lived for about 140 days. More importantly, the median survival time—the point at which half the group had passed away—increased from 128 days in the control group to 170.5 days in the high-dose group. This represents a substantial extension of life, roughly a one-third increase in the median lifespan. The low dose of the virus showed a similar trend toward longer life, but the effect was not strong enough to be statistically certain.
The study revealed that the extra time was not gained by delaying the start of the disease. The mice in all groups began showing signs of weakness, such as limping or difficulty moving their hind legs, at roughly the same age. Instead, the treatment slowed down the speed at which the disease progressed once those symptoms appeared. The mice receiving the high dose spent more time in the early stages of weakness and paralysis before reaching the final, fatal stage. They also lost weight more slowly as the disease advanced, suggesting that their bodies were better able to maintain their overall health for a longer period. The researchers confirmed that the virus successfully delivered the genetic instructions to the spinal cord and that the cells there began producing the Hsp70 protein. This protein was found specifically inside the nerve cells, rather than in the surrounding support cells, indicating that the repair mechanism was happening exactly where it was needed most.
While the treatment extended life and slowed the decline, it did not fully restore the mice's ability to move. Tests of grip strength and balance showed that the treated mice still lost function over time, much like the untreated mice, though the decline may have started slightly later in the high-dose group. This suggests that the therapy is better at preserving the life of the nerve cells than at fixing the damage that has already occurred. The researchers also checked for safety by giving the virus to healthy mice that did not have the disease. These healthy animals showed no signs of illness or weight loss, indicating that the treatment itself was well-tolerated and did not cause toxic side effects. The findings suggest that delivering a steady supply of Hsp70 directly into the nervous system can act as a disease-modifying strategy, slowing the toxic cascade of protein clumping and giving the body more time to function, even if it cannot completely reverse the damage once it has started.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.